UA80298C2 - 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands - Google Patents
1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands Download PDFInfo
- Publication number
- UA80298C2 UA80298C2 UAA200503704A UA2005003704A UA80298C2 UA 80298 C2 UA80298 C2 UA 80298C2 UA A200503704 A UAA200503704 A UA A200503704A UA 2005003704 A UA2005003704 A UA 2005003704A UA 80298 C2 UA80298 C2 UA 80298C2
- Authority
- UA
- Ukraine
- Prior art keywords
- group
- disorders
- heterocyclic group
- triazole
- unbranched
- Prior art date
Links
- ZEWJFUNFEABPGL-UHFFFAOYSA-N 1,2,4-triazole-3-carboxamide Chemical class NC(=O)C=1N=CNN=1 ZEWJFUNFEABPGL-UHFFFAOYSA-N 0.000 title abstract description 4
- 239000003446 ligand Substances 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 208000035475 disorder Diseases 0.000 claims abstract description 10
- 229930003827 cannabinoid Natural products 0.000 claims abstract description 6
- 239000003557 cannabinoid Substances 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 230000005062 synaptic transmission Effects 0.000 claims abstract description 4
- -1 trifluoromethoxy, nitro, amino Chemical group 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 230000009529 traumatic brain injury Effects 0.000 claims description 5
- 125000004306 triazinyl group Chemical group 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000027559 Appetite disease Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 3
- 208000016192 Demyelinating disease Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 208000014094 Dystonic disease Diseases 0.000 claims description 3
- 206010014612 Encephalitis viral Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 206010028813 Nausea Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 206010044565 Tremor Diseases 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 201000007930 alcohol dependence Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 229940065144 cannabinoids Drugs 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 3
- 208000010118 dystonia Diseases 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 230000008693 nausea Effects 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 3
- 208000011117 substance-related disease Diseases 0.000 claims description 3
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 3
- 201000002498 viral encephalitis Diseases 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000006413 ring segment Chemical group 0.000 claims 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 206010012305 Demyelination Diseases 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 206010029216 Nervousness Diseases 0.000 claims 1
- 101100247323 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ras-2 gene Proteins 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- 239000000556 agonist Substances 0.000 abstract description 6
- 239000005557 antagonist Substances 0.000 abstract description 5
- 230000003389 potentiating effect Effects 0.000 abstract description 4
- 239000004031 partial agonist Substances 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 238000002844 melting Methods 0.000 description 17
- 230000008018 melting Effects 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 230000001270 agonistic effect Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- NSPMIYGKQJPBQR-CVMUNTFWSA-N 1h-1,2,4-triazole Chemical class [13CH]=1[15N]=[13CH][15NH][15N]=1 NSPMIYGKQJPBQR-CVMUNTFWSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ZEZPYKWZOOJYIZ-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-(2,4-dichlorophenyl)-1,2,4-triazole-3-carbonyl chloride Chemical compound C=1C=CC=C(Cl)C=1N1N=C(C(=O)Cl)N=C1C1=CC=C(Cl)C=C1Cl ZEZPYKWZOOJYIZ-UHFFFAOYSA-N 0.000 description 2
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 2
- HGRBNXUCZUTDDA-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxylic acid Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1N=C(C(=O)O)N=C1C1=CC=C(Cl)C=C1 HGRBNXUCZUTDDA-UHFFFAOYSA-N 0.000 description 2
- CYAYCOCJAVHQSD-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid Chemical compound CC=1C(C(O)=O)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 CYAYCOCJAVHQSD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
- 108050007331 Cannabinoid receptor Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Natural products CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 150000000178 1,2,4-triazoles Chemical class 0.000 description 1
- HCNMVIBIGGUPKA-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1N1N=C(C(=O)O)N=C1C1=CC=C(Cl)C=C1Cl HCNMVIBIGGUPKA-UHFFFAOYSA-N 0.000 description 1
- OSPQSSUSIPAYEC-UHFFFAOYSA-N 1-(2-chlorophenyl)-5-(2,5-dichlorophenyl)-1,2,4-triazole-3-carboxylic acid Chemical compound C=1C=CC=C(Cl)C=1N1N=C(C(=O)O)N=C1C1=CC(Cl)=CC=C1Cl OSPQSSUSIPAYEC-UHFFFAOYSA-N 0.000 description 1
- QUVINPQBZYNQTA-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-n-(2,2,2-trifluoroethyl)-1,2,4-triazole-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1N=C(C(=O)NCC(F)(F)F)N=C1C1=CC=C(Cl)C=C1Cl QUVINPQBZYNQTA-UHFFFAOYSA-N 0.000 description 1
- KQCMTOWTPBNWDB-UHFFFAOYSA-N 2,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C=C1Cl KQCMTOWTPBNWDB-UHFFFAOYSA-N 0.000 description 1
- CEOCVKWBUWKBKA-UHFFFAOYSA-N 2,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1Cl CEOCVKWBUWKBKA-UHFFFAOYSA-N 0.000 description 1
- RSINFFVFOTUDEC-UHFFFAOYSA-N 2,5-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC(Cl)=CC=C1Cl RSINFFVFOTUDEC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- LMHHFZAXSANGGM-UHFFFAOYSA-N 2-aminoindane Chemical compound C1=CC=C2CC(N)CC2=C1 LMHHFZAXSANGGM-UHFFFAOYSA-N 0.000 description 1
- WHHSHXMIKFVAEK-UHFFFAOYSA-N 2-o-benzyl 1-o-octyl benzene-1,2-dicarboxylate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 WHHSHXMIKFVAEK-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 241000632511 Daviesia arborea Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000003375 cannabimimetic effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- MHDFJESNGMDHQD-UHFFFAOYSA-N dimethyl 2-aminopropanedioate Chemical compound COC(=O)C(N)C(=O)OC MHDFJESNGMDHQD-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- KDMWGAKWRNCERZ-UHFFFAOYSA-N methyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1,2,4-triazole-3-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1N=C(C(=O)OC)N=C1C1=CC=C(Cl)C=C1 KDMWGAKWRNCERZ-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02078966 | 2002-09-19 | ||
| PCT/EP2003/050628 WO2004026301A1 (fr) | 2002-09-19 | 2003-09-17 | Derives de 1h-1,2,4-triazole-3-carboxamide ayant une activite agoniste partielle, agoniste ou antagoniste inverse du recepteur de cannabinoides-cb1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80298C2 true UA80298C2 (en) | 2007-09-10 |
Family
ID=31970417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200503704A UA80298C2 (en) | 2002-09-19 | 2003-09-17 | 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7319110B2 (fr) |
| EP (1) | EP1542678B1 (fr) |
| JP (1) | JP2006501275A (fr) |
| KR (1) | KR100996828B1 (fr) |
| CN (1) | CN1319529C (fr) |
| AR (1) | AR041268A1 (fr) |
| AT (1) | ATE458479T1 (fr) |
| AU (1) | AU2003299024B2 (fr) |
| BR (1) | BR0312020A (fr) |
| CA (1) | CA2491394C (fr) |
| DE (1) | DE60331444D1 (fr) |
| DK (1) | DK1542678T3 (fr) |
| ES (1) | ES2341540T3 (fr) |
| HK (1) | HK1078796A1 (fr) |
| HR (1) | HRP20050053A2 (fr) |
| IL (1) | IL165611A (fr) |
| MX (1) | MXPA05002862A (fr) |
| NO (1) | NO20051870L (fr) |
| PL (1) | PL375020A1 (fr) |
| PT (1) | PT1542678E (fr) |
| RU (1) | RU2325382C2 (fr) |
| SI (1) | SI1542678T1 (fr) |
| UA (1) | UA80298C2 (fr) |
| WO (1) | WO2004026301A1 (fr) |
| ZA (1) | ZA200500133B (fr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6897240B2 (en) * | 2002-05-08 | 2005-05-24 | The Regents Of The University Of California | Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use |
| KR20060005378A (ko) * | 2003-04-21 | 2006-01-17 | 다이이찌 세이야꾸 가부시기가이샤 | ５원 복소환 유도체 |
| US7223780B2 (en) * | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| CA2543338A1 (fr) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Nouvelles utilisations medicales de composes a activite antagoniste de cb1 et traitement combine impliquant ces composes |
| WO2005051298A2 (fr) * | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Nouvelles substances thyromimetiques contenant du phosphore |
| US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
| ES2255834B1 (es) * | 2004-09-14 | 2008-01-16 | Laboratorios Del Dr. Esteve, S.A. | Nuevos derivados 1,2,4-triazol-3-carboxamida. |
| MX2007003648A (es) * | 2004-10-01 | 2007-06-11 | Hoffmann La Roche | Derivados de eter sustituido con hexafluoroisopropanol. |
| RU2007119315A (ru) | 2004-10-25 | 2008-11-27 | Зольвай Фармасьютиклз Гмбх (De) | Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний |
| US7494985B2 (en) * | 2004-11-03 | 2009-02-24 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use |
| WO2006117307A2 (fr) * | 2005-04-29 | 2006-11-09 | Janssen Pharmaceutica N.V. | Derives de benzotriazole tenant lieu d'antagonistes du recepteur cannabinoide |
| CA2613678A1 (fr) | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Nouveaux ligands des recepteurs des cannabinoides, compositions pharmaceutiques contenant ces ligands, et procede servant a leur preparation |
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| TW200726765A (en) * | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| JP2008544982A (ja) * | 2005-06-29 | 2008-12-11 | アストラゼネカ・アクチエボラーグ | アルファ７ニコチン性受容体調節剤としてのチオフェン−２−カルボキサミド誘導体 |
| NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
| FR2894579B1 (fr) * | 2005-12-12 | 2008-01-18 | Sanofi Aventis Sa | Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique. |
| JP5448164B2 (ja) | 2006-07-28 | 2014-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を変調する化合物 |
| WO2008033572A1 (fr) * | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Promédicaments à base de carbamate d'acyloxyalkyle, procédés de synthèse et utilisation |
| EP2377863A1 (fr) | 2007-01-04 | 2011-10-19 | Prosidion Limited | Agonistes du GPCR de piperidine |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
| CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| US20100048625A1 (en) | 2007-01-04 | 2010-02-25 | Matthew Colin Thor Fyfe | Piperidine gpcr agonists |
| CN101302200B (zh) * | 2007-05-09 | 2011-04-20 | 上海医药工业研究院 | 制备n-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺的方法 |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| WO2009061652A1 (fr) | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Composés modulant le récepteur cb2 |
| WO2009105509A1 (fr) | 2008-02-21 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Composés amine et éther qui modulent le récepteur cb2 |
| JP5749162B2 (ja) | 2008-07-10 | 2015-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するスルホン化合物 |
| AP2011005674A0 (en) * | 2008-09-25 | 2011-04-30 | Boehringer Ingelheim Int | Sulfonyl compounds which selectively modulate the CB2 receptor. |
| WO2010077836A2 (fr) | 2009-01-05 | 2010-07-08 | Boehringer Ingelheim International Gmbh | Composés pyrrolidines qui modulent le récepteur cb2 |
| WO2010079241A1 (fr) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Utilisation d'antagonistes et/ou d'agonistes inverses des récepteurs cb1 pour la préparation de médicaments qui augmentent l'excitabilité des motoneurones |
| US8889670B2 (en) | 2009-02-18 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the CB2 receptor |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| WO2010147791A1 (fr) | 2009-06-16 | 2010-12-23 | Boehringer Ingelheim International Gmbh | Dérivés d'azétidine 2-carboxamide qui modulent le récepteur cb2 |
| WO2011037795A1 (fr) | 2009-09-22 | 2011-03-31 | Boehringer Ingelheim International Gmbh | Composés à modulation sélective du récepteur cb2 |
| EP2523936A1 (fr) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Composés qui modulent le récepteur cb2 |
| US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
| EP2595959B1 (fr) | 2010-07-22 | 2015-11-04 | Boehringer Ingelheim International GmbH | Composés sulfonylés qui modulent le récepteur cb2 |
| CN102558157B (zh) * | 2010-12-20 | 2014-04-30 | 中国科学院上海药物研究所 | 羟乙基三唑类化合物或氨乙基三唑类化合物及其制备方法和用途 |
| CN102731418B (zh) * | 2012-07-15 | 2015-03-11 | 浙江大学 | 1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途 |
| CN104603129A (zh) * | 2012-09-17 | 2015-05-06 | 霍夫曼-拉罗奇有限公司 | 三唑甲酰胺衍生物 |
| EP2803668A1 (fr) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles |
| EP3152200A1 (fr) | 2014-06-06 | 2017-04-12 | Research Triangle Institute | Agonistes du récepteur de l'apeline (apj) et leurs utilisations |
| US9718789B2 (en) | 2015-01-30 | 2017-08-01 | Neurocrine Biosciences, Inc. | Substituted triazoles and methods relating thereto |
| MX2018006979A (es) | 2015-12-09 | 2019-05-16 | Res Triangle Inst | Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos. |
| CN114507217A (zh) | 2016-10-12 | 2022-05-17 | 三角研究所 | 杂环爱帕琳肽受体(apj)激动剂及其用途 |
| US11655238B2 (en) | 2018-11-20 | 2023-05-23 | Shanghaitech University | MMPL3 inhibitors, compositions and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58194866A (ja) * | 1982-05-07 | 1983-11-12 | Kureha Chem Ind Co Ltd | トリアゾ−ル誘導体及び該誘導体を含有する除草剤 |
| DE3316300A1 (de) * | 1982-05-07 | 1983-11-24 | Kureha Kagaku Kogyo K.K., Tokyo | Heribizide zusammensetzung mit einem gehalt an einem derivat des 1,2,4-triazols als wirkstoff |
| DE3817192A1 (de) * | 1988-05-20 | 1989-11-30 | Hoechst Ag | 1,2,4-triazolderivate enthaltende pflanzenschuetzende mittel sowie neue derivate des 1,2,4-triazols |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| DE4225778A1 (de) * | 1992-08-04 | 1994-02-17 | Hoechst Ag | 1,2,4-Triazolyl-3-carbonsäure-4-aminopiperidide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel, insbesondere Fungizide |
| FR2741621B1 (fr) * | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| EP1224173B1 (fr) | 1999-10-18 | 2005-10-12 | The University Of Connecticut | Derives de pyrazole comme antagonistes des recepteurs des cannabinoides |
| JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
-
2003
- 2003-09-16 US US10/662,477 patent/US7319110B2/en not_active Expired - Fee Related
- 2003-09-16 AR ARP030103347A patent/AR041268A1/es unknown
- 2003-09-17 DK DK03797318.7T patent/DK1542678T3/da active
- 2003-09-17 KR KR1020057004584A patent/KR100996828B1/ko not_active IP Right Cessation
- 2003-09-17 MX MXPA05002862A patent/MXPA05002862A/es active IP Right Grant
- 2003-09-17 CA CA2491394A patent/CA2491394C/fr not_active Expired - Fee Related
- 2003-09-17 ES ES03797318T patent/ES2341540T3/es not_active Expired - Lifetime
- 2003-09-17 EP EP03797318A patent/EP1542678B1/fr not_active Expired - Lifetime
- 2003-09-17 BR BR0312020-1A patent/BR0312020A/pt not_active IP Right Cessation
- 2003-09-17 WO PCT/EP2003/050628 patent/WO2004026301A1/fr active Application Filing
- 2003-09-17 UA UAA200503704A patent/UA80298C2/uk unknown
- 2003-09-17 AT AT03797318T patent/ATE458479T1/de active
- 2003-09-17 AU AU2003299024A patent/AU2003299024B2/en not_active Ceased
- 2003-09-17 CN CNB038173522A patent/CN1319529C/zh not_active Expired - Fee Related
- 2003-09-17 PT PT03797318T patent/PT1542678E/pt unknown
- 2003-09-17 RU RU2005103244/04A patent/RU2325382C2/ru not_active IP Right Cessation
- 2003-09-17 DE DE60331444T patent/DE60331444D1/de not_active Expired - Lifetime
- 2003-09-17 SI SI200331803T patent/SI1542678T1/sl unknown
- 2003-09-17 PL PL03375020A patent/PL375020A1/xx not_active Application Discontinuation
- 2003-09-17 JP JP2004537155A patent/JP2006501275A/ja active Pending
-
2004
- 2004-12-07 IL IL165611A patent/IL165611A/en not_active IP Right Cessation
-
2005
- 2005-01-06 ZA ZA200500133A patent/ZA200500133B/en unknown
- 2005-01-19 HR HR20050053A patent/HRP20050053A2/xx not_active Application Discontinuation
- 2005-04-18 NO NO20051870A patent/NO20051870L/no not_active Application Discontinuation
- 2005-12-01 HK HK05110963A patent/HK1078796A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100996828B1 (ko) | 2010-11-29 |
| WO2004026301A1 (fr) | 2004-04-01 |
| DE60331444D1 (de) | 2010-04-08 |
| US7319110B2 (en) | 2008-01-15 |
| JP2006501275A (ja) | 2006-01-12 |
| RU2325382C2 (ru) | 2008-05-27 |
| EP1542678B1 (fr) | 2010-02-24 |
| NO20051870L (no) | 2005-06-03 |
| RU2005103244A (ru) | 2005-06-27 |
| PL375020A1 (en) | 2005-11-14 |
| KR20050057399A (ko) | 2005-06-16 |
| CN1671377A (zh) | 2005-09-21 |
| CA2491394A1 (fr) | 2004-04-01 |
| HK1078796A1 (en) | 2006-03-24 |
| CA2491394C (fr) | 2010-06-15 |
| AU2003299024A1 (en) | 2004-04-08 |
| IL165611A (en) | 2010-04-15 |
| ZA200500133B (en) | 2005-11-01 |
| EP1542678A1 (fr) | 2005-06-22 |
| MXPA05002862A (es) | 2005-05-27 |
| PT1542678E (pt) | 2010-05-25 |
| AR041268A1 (es) | 2005-05-11 |
| US20040106614A1 (en) | 2004-06-03 |
| BR0312020A (pt) | 2005-03-22 |
| ES2341540T3 (es) | 2010-06-22 |
| IL165611A0 (en) | 2006-01-15 |
| AU2003299024B2 (en) | 2008-03-06 |
| DK1542678T3 (da) | 2010-06-07 |
| HRP20050053A2 (en) | 2005-04-30 |
| SI1542678T1 (sl) | 2010-07-30 |
| ATE458479T1 (de) | 2010-03-15 |
| CN1319529C (zh) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA80298C2 (en) | 1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands | |
| RU2301804C2 (ru) | Производные тиазола, имеющие антагонистическую, агонистическую или частично агонистическую св1-активность | |
| CA2356263C (fr) | Derives d'aminopyrazole | |
| RU2360904C2 (ru) | 1,3,5-тризамещенные производные 4,5-дигидро-1н-пиразола, обладающие св1-антагонистической активностью | |
| KR100950431B1 (ko) | Ｃｂ1 효능 활성, ｃｂ1 부분 효능 활성 또는 ｃｂ1 길항 활성을 갖는 1ｈ-이미다졸 유도체 및 이를 함유하는 약제학적 조성물 | |
| AU2010244685B2 (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
| WO2015038778A1 (fr) | Activateurs substitués de l'urée-kinase eif2α | |
| ZA200201485B (en) | N-Heterocyclic derivatives as NOS inhibitors. | |
| WO2006087355A1 (fr) | Derives de 1h-imidiazole en tant que modulateurs des recepteurs cannabinoides cb2 | |
| JP2009523748A (ja) | α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用 | |
| KR20150038705A (ko) | 글루카곤 수용체 조절자 | |
| JP2012505920A (ja) | スフィンゴシン１リン酸塩受容体拮抗薬 | |
| AU2010311466B2 (en) | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them | |
| CA2696429A1 (fr) | Composes pyrroliques ayant une activite agoniste de recepteur de sphingosine-1-phosphate ou une activite biologique antagoniste | |
| CN102264710B (zh) | 半胱氨酸蛋白酶抑制剂 | |
| ES2909709T3 (es) | Inhibidores del receptor 2 activado por proteasa | |
| CZ36194A3 (en) | Amidetetrazoles inhibiting cholesterol acyltransferase | |
| JP2009179562A (ja) | グリシントランスポーター阻害剤 | |
| EP1756066B1 (fr) | Derives d'imidazole tetrasubstitues utilises comme modulateurs du recepteur des cannabinoides cb1 a activite de selectivite de sous-types du recepteur cb1/cb2 elevee | |
| TW200406391A (en) | 1H-1,2,4-Triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity | |
| JP2009185010A (ja) | グリシントランスポーター阻害剤を含有する医薬 | |
| UA82908C2 (en) | 1h-imidazole derivatives as cannabinoid receptor modulators | |
| TW200305411A (en) | Thiazole derivatives having CB-antagonistic, agonistic or partial agonistic activity | |
| SA05260148B1 (ar) | مشتقات إيميدازول بها أربعة استبدالات للاستخدام كمنظمات لمستقبل شبيه القنب cb1 بدرجة عالية من الانتقائية تجاه النوع الفرعي لمستقبلات cb1/cb2 |